US Patent Issued to Acrivon Therapeutics on Oct. 7 for "Methods and systems for treating disease using an ATR/Chk1 signaling pathway inhibitor" (Swedish, American Inventors)

ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,433,888, issued on Oct. 7, was assigned to Acrivon Therapeutics Inc. (Watertown, Mass.).

"Methods and systems for treating disease using an ATR/Chk1 signaling pathway inhibitor" was invented by Peter Blume-Jensen (Cambridge, Mass.), James Dunyak (Cambridge, Mass.), Kristina Masson (Lund, Sweden), Ayesha Murshid (Milford, Mass.), Michail Shipitsin (Brookline, Mass.) and Caroline Maria Wigerup (Dalby, Sweden).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are methods and systems for determining and/or validating response to a checkpoint kinase 1 (Chk1) inhibitor, a Wee1 inhibitor, an ATR inhibitor, or a combination thereof, and methods of ad...